Elevated postmortem striatal t-DARPP expression in schizophrenia and associations with DRD2/ANKK1 polymorphism

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 53, Issue , 2014, Pages 123-128

  Kunii, Yasuto ^a   Miura, Itaru ^a   Matsumoto, Junya ^a   Hino, Mizuki ^a   Wada, Akira ^a   Niwa, Shin ichi ^a   Nawa, Hiroyuki ^b   Sakai, Miwako ^b   Someya, Toshiyuki ^c   Takahashi, Hitoshi ^b   Kakita, Akiyoshi ^b   Yabe, Hirooki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

DARPP 32; Dopamine D2 receptor gene (DRD2); Schizophrenia; Taq1A polymorphism; Truncated DARPP

Indexed keywords

ANKK1 PROTEIN, HUMAN; CALCINEURIN; DOPAMINE 2 RECEPTOR; PHOSPHOPROTEIN DARPP 32; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ANALYSIS OF VARIANCE; CORPUS STRIATUM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; POSTMORTEM CHANGE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CALCINEURIN; CORPUS STRIATUM; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMORTEM CHANGES; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84899000163     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2014.03.014     Document Type: Article

References (39)

1. Albert K.A., Hemmings H.C., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 2002, 59:705-712.
2. Baracskay K.L., Haroutunian V., Meador-Woodruff J.H. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse 2006, 60:271-279.
3. Belkhiri A., Dar A.A., Zaika A., Kelley M., El-Rifai W. t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 2008, 68:395-403.
4. Berger B., Febvret A., Greengard P., Goldman-Rakic P.S. DARPP-32, a phosphoprotein enriched in dopaminoceptive neurons bearing dopamine D1 receptors: distribution in the cerebral cortex of the newborn and adult rhesus monkey. J Comp Neurol 1990, 299:327-348.
5. Brene S., Hall H., Lindefors N., Karlsson P., Halldin C., Sedvall G. Distribution of messenger RNAs for D1 dopamine receptors and DARPP-32 in striatum and cerebral cortex of the cynomolgus monkey: relationship to D1 dopamine receptors. Neuroscience 1995, 67:37-48.
6. Dubertret C., Bardel C., Ramoz N., Martin P.M., Deybach J.C., Ades J., et al. A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:492-499.
7. El-Rifai W., Smith M.F., Li G., Beckler A., Carl V.S., Montgomery E., et al. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res 2002, 62:4061-4064.
8. Golimbet V.E., Aksenova M.G., Nosikov V.V., Orlova V.A., Kaleda V.G. Analysis of the linkage of the Taq1A and Taq1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings. Neurosci Behav Physiol 2003, 33:223-225.
9. Grandy D.K., Zhang Y., Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet 1993, 2:2197.
10. Gu L., Waliany S., Kane S.E. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance. PLoS One 2009, 4:e6220.
11. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 2001, 98:4746-4751.
12. Hill C., Roberts S., Keks N., Dean B., Mackinnon A., Copolov D. Diagnostic instrument for brain studies-revised 2005, Mental Health Research Institute, Victoria, Australia.
13. Ishikawa M., Mizukami K., Iwakiri M., Asada T. Immunohistochemical and immunoblot analysis of dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1177-1181.
14. Jönsson E., Nöthen M., Grünhage F., Farde L., Nakashima Y., Propping P., et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999, 4:290-296.
15. Kozlovsky N., Scarr E., Dean B., Agam G. Postmortem brain calcineurin protein levels in schizophrenia patients are not different from controls. Schizophr Res 2006, 83:173-177.
16. Kunii Y., Ikemoto K., Wada A., Yang Q., Kusakabe T., Suzuki T., et al. Detailed DARPP-32 expression profiles in postmortem brains from patients with schizophrenia: an immunohistochemical study. Med Mol Morphol 2011, 44:190-199.
17. Kunii Y., Yabe H., Wada A., Yang Q., Nishiura K., Niwa S. Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1139-1143.
18. Kunii Y., Hyde T.M., Ye T., Li C., Kolachana B., Dickinson D., et al. Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression. Mol Psychiatry 2014, 19(2):192-199.
19. Kwon J.S., Kim E., Kang D.H., Choi J.S., Yu K.S., Jang I.J., et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol 2008, 18:897-907.
20. Laakso A., Pohjalainen T., Bergman J., Kajander J., Haaparanta M., Solin O., et al. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal l-amino acid decarboxylase in healthy subjects. Pharmacogenet Genomics 2005, 15:387-391.
21. Lucht M., Rosskopf D. Comment on "Genetically determined differences in learning from errors". Science 2008, 321:200. [author reply].
22. Meyer-Lindenberg A., Straub R.E., Lipska B.K., Verchinski B.A., Goldberg T., Callicott J.H., et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 2007, 117:672-682.
23. Miura I., Takeuchi S., Katsumi A., Mori A., Kanno K., Yang Q., et al. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. J Clin Psychopharmacol 2012, 32:106-109.
24. Neville M.J., Johnstone E.C., Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004, 23:540-545.
25. Nishiura K., Kunii Y., Wada A., Matsumoto J., Yang Q., Ikemoto K., et al. Profiles of DARPP-32 in the insular cortex with schizophrenia: a postmortem brain study. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1901-1907.
26. Ouimet C.C., Miller P.E., Hemmings H.C., Walaas S.I., Greengard P. DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J Neurosci 1984, 4:111-124.
27. Ouimet C.C., LaMantia A.S., Goldman-Rakic P., Rakic P., Greengard P. Immunocytochemical localization of DARPP-32, a dopamine and cyclic-AMP-regulated phosphoprotein, in the primate brain. J Comp Neurol 1992, 323:209-218.
28. Parsons M.J., Mata I., Beperet M., Iribarren-Iriso F., Arroyo B., Sainz R., et al. A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate. Psychiatr Genet 2007, 17:159-163.
29. Rusnak F., Mertz P. Calcineurin: form and function. Physiol Rev 2000, 80:1483-1521.
30. Schafer M., Rujescu D., Giegling I., Guntermann A., Erfurth A., Bondy B., et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001, 158:802-804.
31. Suzuki A., Mihara K., Kondo T., Tanaka O., Nagashima U., Otani K., et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenet Genomics 2000, 10:335-341.
32. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 2004, 44:269-296.
33. Torres K.C., Souza B.R., Miranda D.M., Nicolato R., Neves F.S., Barros A.G., et al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:214-219.
34. Vangamudi B., Peng D.F., Cai Q., El-Rifai W., Zheng W., Belkhiri A. t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer. Mol Cancer 2010, 9:240.
35. Wada A., Kunii Y., Ikemoto K., Yang Q., Hino M., Matsumoto J., et al. Increased ratio of calcineurin immunoreactive neurons in the caudate nucleus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012, 37:8-14.
36. Walaas S.I., Greengard P. DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain. J Neurosci 1984, 4:84-98.
37. Yger M., Girault J.A. DARPP-32, Jack of all trades. . master of which?. Front Behav Neurosci 2011, 5:56.
38. Zhan L., Kerr J.R., Lafuente M.J., Maclean A., Chibalina M.V., Liu B., et al. Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder. Neuropathol Appl Neurobiol 2011, 37:206-219.
39. Zhang J.P., Lencz T., Malhotra A.K. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010, 167:763-772.